FDA Grants PharmaTher Pre-IND Meeting For Treatment Of Parkinson’s With Ketamine

PharmaTher Inc (CSE: PHRM) this morning announced that the US Food and Drug Administration has granted the company a pre-investigational new drug meeting. The meeting, which was filed for earlier this week, is in connection with the clinical development of ketamine for use against Parkinson’s Disease, as well as a currently proposed phase 2 clinical study for using the psychedelic compound in the treatment of levodopa-induced dyskinesia associated with Parkinson’s.

The current timeline for the written response meeting indicates that the meeting should be conducted by the end of January 2021. Furthermore, PharmaTher has stated that it has substantially completed its application for an investigational new drug, and upon receiving responses from the FDA, intends to file and begin a phase 2 study on the use of ketamine for the treatment of levodopa induced dyskinesia, or the loss of motor controls, within the first quarter of 2021.

The meeting to be conducted with the FDA is anticipated to provide the required information to submit this application, and enable the company to continue along the FDA regulatory pathway.

“We are pleased that our initiatives focused on the FDA regulatory pathway for ketamine continues its momentum and the IND builds a foundation where we can develop an FDA approved ketamine for not only Parkinson’s disease, but also for the millions of people worldwide affected by movement disorders, depression and pain.”

Fabio Chianelli, CEO of PharmaTher

PharmaTher last traded at $0.27 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

Giant Mining Encounters Native Copper As Hole MHB-34 Hits 563 Metres Depth

Verses Hits Commercialization Stage With Genius AI Platform

Related News

PharmaTher Receives FDA Approval For Ketamine Trial For Parkinson’s

PharmaTher Holdings (CSE: PHRM) has seen the US FDA approve the firms application for an...

Monday, May 17, 2021, 09:15:31 AM

PharmaTher Collaborates For Research On Psychedelic Microdosing Tech

PharmaTher Inc (CSE: PHRM) this morning announced that it will be conducting further research related...

Tuesday, February 23, 2021, 07:25:33 AM

PharmaTher To Commence Phase 2 Clinical Study On Ketamine In Q2 2021

Pharmather Inc (CSE: PHRM) is successfully progressing on the development of its proposed phase 2...

Thursday, February 4, 2021, 08:28:04 AM

Pharmather Enters Exclusive Arrangement For Psychedelic Delivery Tech

Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive license...

Thursday, October 22, 2020, 08:13:19 AM

Biogen Wins Approval with FDA for Alzheimer’s Drug

This morning Biogen (NASDAQ:BIIB) received approval from the FDA for their Alzheimer’s drug aducanumab. The...

Monday, June 7, 2021, 11:49:16 AM